Tirzepatide
13 research papers indexed
Frias 2021 — SURPASS-2 Tirzepatide vs Semaglutide T2D
1003
New England Journal of Medicine
·2021RCTHumanType 2 diabetesSourcePhase 3
Aronne 2025 — SURMOUNT-5 Tirzepatide vs Semaglutide Obesity Head-to-Head
451
New England Journal of Medicine
·2025RCTHumanObesity or overweight with weight-related comorbiditySourceRCT
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis
0
JAMA Network Open
·2026Clinical TrialHumanObesity with concomitant weight-inducing medications
Aronne 2024 — SURMOUNT-4 (Tirzepatide Withdrawal/Regain)
0
JAMA
·2024RCTHumanObesity/overweight + comorbiditySourcePhase 3
Jastreboff 2022 — SURMOUNT-1 Tirzepatide Pivotal
0
New England Journal of Medicine
·2022RCTHumanObesity or overweightSourcePhase 3
Packer 2024 — SUMMIT HFpEF Trial
0
New England Journal of Medicine
·2024RCTHumanHeart failure with preserved ejection fraction and obesitySourceRCT
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis
0
Obesity
·2026Clinical TrialHumanObesity or overweight in Japanese adults
Malhotra 2024 — SURMOUNT-OSA Tirzepatide
0
New England Journal of Medicine
·2024RCTHumanObstructive sleep apnea with obesitySourceRCT
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis
0
Obesity
·2026Clinical TrialHumanObesity without major psychopathology
Aronne 2025 — SURMOUNT-5 (Tirzepatide vs Semaglutide)
0
New England Journal of Medicine
·2025RCTHumanObesity/overweightSourcePhase 3
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA
0
Nature Medicine
·2026Clinical TrialHumanOSA-related cardiometabolic risk
Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics
0
BMJ Open Diabetes Research & Care
·2026Clinical TrialHumanType 2 diabetes
Nicholls 2025 — SURPASS-CVOT Tirzepatide
0
New England Journal of Medicine
·2025RCTHumanCV outcomes in T2D and obesitySourceRCT